Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus

Hormone and Metabolic Research

Volumn 46, Issue 13, 2014, Pages 943-949

  Rosenstock, J ^a   Truitt, K E ^b   Baz Hecht, M ^b   Ford, D M ^b   Tao, B ^b   Chou, H S ^b  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

bile acid sequestrants; cholesterol; glucose; glycemic control; thiazolidinediones; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALLYLAMINE; COLESEVELAM; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID; PIOGLITAZONE; PLACEBO;

ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG COMBINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ALLYLAMINE; BLOOD GLUCOSE; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEAST-SQUARES ANALYSIS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84938861833     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1383648     Document Type: Article

References (20)

1. American Diabetes Association Standards of medical care in diabetes - 2014. Diabetes Care: 2014; 37 01 S14 S80
2. Bays H. E., Goldberg R. B., Truitt K. E., Jones M. R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med: 2008; 168 1975 1983
3. Fonseca V. A., Rosenstock J., Wang A. C., Truitt K. E., Jones M. R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care: 2008; 31 1479 1484
4. Goldberg R. B., Fonseca V. A., Truitt K. E., Jones M. R. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med: 2008; 168 1531 1540
5. Nwose O. M., Jones M. R. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes: 2013; 6 75 79
6. Potthoff M. J., Potts A., He T., Duarte J. A., Taussig R., Mangelsdorf D. J., Kliewer S. A., Burgess S. C. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol: 2013; 304 G371 G380
7. Beysen C., Murphy E. J., Deines K., Chan M., Tsang E., Glass A., Turner S. M., Protasio J., Riiff T., Hellerstein M. K. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia: 2012; 55 432 442
8. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2008; 31 01 S55 S60
9. Otvos J. D., Jeyarajah E. J., Bennett D. W., Krauss R. M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem: 1992; 38 1632 1638
10. Rosenstock J., Rigby S. P., Ford D. M., Tao B., Chou H. S. The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes. Horm Metab Res: 2014; 46 348 353
11. Handelsman Y., Mechanick J. I., Blonde L., Grunberger G., Bloomgarden Z. T., Bray G. A., Dagogo-Jack S., Davidson J. A., Einhorn D., Ganda O., Garber A. J., Hirsch I. B., Horton E. S., Ismail-Beigi F., Jellinger P. S., Jones K. L., Jovanovic L., Lebovitz H., Levy P., Moghissi E. S., Orzeck E. A., Vinik A. I., Wyne K. L. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract: 2011; 17 02 1 53
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA: 2001; 285 2486 2497
13. Stone N. J., Robinson J., Lichtenstein A. H., Merz C. N., Blum C. B., Eckel R. H., Goldberg A. C., Gordon D., Levy D., Lloyd-Jones D. M., McBride P., Schwartz J. S., Shero S. T., Smith S. C. Jr, Watson K., Wilson P. W. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation: 2014; 129 02 S1 S45
14. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA: 1984; 251 365 374
15. Garvey W. T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., Pugh K., Jenkins A. J., Klein R. L., Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes: 2003; 52 453 462
16. Brunzell J. D., Davidson M., Furberg C. D., Goldberg R. B., Howard B. V., Stein J. H., Witztum J. L. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care: 2008; 31 811 822
17. Rosenson R. S., Rigby S. P., Jones M. R., Chou H. S. Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus. Cardiovasc Drugs Ther: 2014; 28 229 236
18. Goldberg R. B., Rosenson R. S., Hernandez-Triana E., Misir S., Jones M. R. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol: 2012; 6 318 324
19. Rosenson R. S., Abby S. L., Jones M. R. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis: 2009; 204 342 344
20. Henry R. R., Aroda V. R., Mudaliar S., Garvey W. T., Chou H. S., Jones M. R. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab: 2012; 14 40 46